| Nov 20 |
Editas Medicine, Inc. (EDIT) Presents at Stifel 2024 Healthcare Conference (Transcript)
|
| Nov 11 |
CRISPR, Beam, other gene editing names up significantly
|
| Nov 6 |
Editas Medicine upgraded at Evercore on CRISPR platform
|
| Nov 6 |
Growth Investors: Industry Analysts Just Upgraded Their Editas Medicine, Inc. (NASDAQ:EDIT) Revenue Forecasts By 19%
|
| Nov 5 |
Editas Medicine Downgraded by Raymond James Amid Strategic Shift and Program Uncertainty
|
| Nov 5 |
Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y
|
| Nov 5 |
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
|
| Nov 5 |
Editas Medicine Third Quarter 2024 Earnings: Misses Expectations
|
| Nov 4 |
Editas downgraded to market perform by Raymond James
|
| Nov 4 |
Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates
|
